New 44,000 square-metre biopharmaceutical facility will include offices, research labs and manufacturing space
MONTREAL—SNC-Lavalin Inc. has landed a $12.5 million contract to design a new facility for biopharmaceutical company Medicago.
To be located within Quebec City’s Estimauville innovation park, the site will be designed to consolidate all of the Quebec-based company’s Canadian operations under one roof, housing office space, research and development as well as commercial production.
“We are very proud to be part of a local project that, once complete, will export vaccines to foreign markets and help Canada meet its seasonal and pandemic flu vaccine needs,” Ian Edwards, president of Infrastructure at SNC, said.
Under the agreement, SNC will carry out preliminary and detailed engineering services, procurement of equipment critical to the process fabrication and the complete supply of automation integration services for the 44,000 square-metre facility.
The Montreal-based engineering firm expects construction to begin this fall.